JP2017531016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531016A5 JP2017531016A5 JP2017520427A JP2017520427A JP2017531016A5 JP 2017531016 A5 JP2017531016 A5 JP 2017531016A5 JP 2017520427 A JP2017520427 A JP 2017520427A JP 2017520427 A JP2017520427 A JP 2017520427A JP 2017531016 A5 JP2017531016 A5 JP 2017531016A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- heterocycle
- stereoisomer
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 4
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- MESFXNGUDNODTJ-UHFFFAOYSA-N 2h-thiazine 1,1-dioxide Chemical compound O=S1(=O)NC=CC=C1 MESFXNGUDNODTJ-UHFFFAOYSA-N 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- -1 —OH 2 Chemical group 0.000 claims 3
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims 2
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 206010021263 IgA nephropathy Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064234P | 2014-10-15 | 2014-10-15 | |
| US62/064,234 | 2014-10-15 | ||
| PCT/US2015/055421 WO2016061161A1 (en) | 2014-10-15 | 2015-10-14 | Aldosterone synthase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531016A JP2017531016A (ja) | 2017-10-19 |
| JP2017531016A5 true JP2017531016A5 (https=) | 2017-11-30 |
| JP6279812B2 JP6279812B2 (ja) | 2018-02-14 |
Family
ID=54352516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520427A Active JP6279812B2 (ja) | 2014-10-15 | 2015-10-14 | アルドステロンシンターゼ阻害薬 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9745289B2 (https=) |
| EP (1) | EP3207039B1 (https=) |
| JP (1) | JP6279812B2 (https=) |
| KR (1) | KR102441634B1 (https=) |
| CN (1) | CN107108587B (https=) |
| AP (1) | AP2017009829A0 (https=) |
| AR (1) | AR102266A1 (https=) |
| AU (1) | AU2015333611B2 (https=) |
| CA (1) | CA2964754C (https=) |
| CL (1) | CL2017000827A1 (https=) |
| CO (1) | CO2017003305A2 (https=) |
| CY (1) | CY1121650T1 (https=) |
| DK (1) | DK3207039T3 (https=) |
| EA (1) | EA031766B1 (https=) |
| ES (1) | ES2724555T3 (https=) |
| HR (1) | HRP20190896T1 (https=) |
| HU (1) | HUE043783T2 (https=) |
| IL (1) | IL251200B (https=) |
| LT (1) | LT3207039T (https=) |
| ME (1) | ME03381B (https=) |
| MX (1) | MX369025B (https=) |
| NZ (1) | NZ729688A (https=) |
| PE (1) | PE20170696A1 (https=) |
| PH (1) | PH12017500595B1 (https=) |
| PL (1) | PL3207039T3 (https=) |
| PT (1) | PT3207039T (https=) |
| RS (1) | RS58651B1 (https=) |
| SG (1) | SG11201701850UA (https=) |
| SI (1) | SI3207039T1 (https=) |
| TR (1) | TR201907755T4 (https=) |
| TW (1) | TWI731842B (https=) |
| UA (1) | UA118717C2 (https=) |
| WO (1) | WO2016061161A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6707084B2 (ja) * | 2014-12-02 | 2020-06-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロンシンターゼ阻害薬 |
| JP7227157B2 (ja) * | 2016-12-29 | 2023-02-21 | フェーズバイオ ファーマシューティカルズ，インコーポレイテッド | 金属酵素阻害剤化合物 |
| EP3962903A1 (en) | 2019-05-01 | 2022-03-09 | Boehringer Ingelheim International GmbH | (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
| JP2023541601A (ja) | 2020-09-10 | 2023-10-03 | プレシリックス・ナームローゼ・ベンノートシヤープ | Ｆａｐに対する抗体フラグメント |
| TW202339719A (zh) | 2021-12-14 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療慢性腎臟病之醛固酮合成酶抑制劑 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| CN121181527A (zh) * | 2024-06-21 | 2025-12-23 | 江苏豪森药业集团有限公司 | 双稠环类化合物、及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201026688A (en) * | 2008-10-07 | 2010-07-16 | Schering Corp | Benzodioxan analogues as alpha2C adrenergic receptor modulators |
| NZ596302A (en) * | 2009-05-15 | 2014-01-31 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
| AR088989A1 (es) * | 2011-11-30 | 2014-07-23 | Hoffmann La Roche | Derivados biciclicos de dihidroisoquinolin-1-ona |
| CA2886117C (en) * | 2012-10-05 | 2022-05-31 | Merck Sharp & Dohme Corp. | Indoline compounds and their use as aldosterone synthase inhibitors |
| KR20150118158A (ko) * | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| JP6067181B2 (ja) * | 2013-04-30 | 2017-01-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロンシンターゼ阻害薬 |
| HUE039981T2 (hu) * | 2014-07-24 | 2019-02-28 | Boehringer Ingelheim Int | Aldoszteron szintáz inhibitorok |
-
2015
- 2015-10-14 WO PCT/US2015/055421 patent/WO2016061161A1/en not_active Ceased
- 2015-10-14 HR HRP20190896TT patent/HRP20190896T1/hr unknown
- 2015-10-14 UA UAA201704599A patent/UA118717C2/uk unknown
- 2015-10-14 EA EA201790830A patent/EA031766B1/ru not_active IP Right Cessation
- 2015-10-14 RS RS20190501A patent/RS58651B1/sr unknown
- 2015-10-14 AP AP2017009829A patent/AP2017009829A0/en unknown
- 2015-10-14 PE PE2017000710A patent/PE20170696A1/es unknown
- 2015-10-14 ES ES15785014T patent/ES2724555T3/es active Active
- 2015-10-14 EP EP15785014.0A patent/EP3207039B1/en active Active
- 2015-10-14 CA CA2964754A patent/CA2964754C/en active Active
- 2015-10-14 AU AU2015333611A patent/AU2015333611B2/en not_active Ceased
- 2015-10-14 TW TW104133758A patent/TWI731842B/zh not_active IP Right Cessation
- 2015-10-14 MX MX2017004852A patent/MX369025B/es active IP Right Grant
- 2015-10-14 CN CN201580053796.XA patent/CN107108587B/zh active Active
- 2015-10-14 SG SG11201701850UA patent/SG11201701850UA/en unknown
- 2015-10-14 KR KR1020177012975A patent/KR102441634B1/ko active Active
- 2015-10-14 LT LTEP15785014.0T patent/LT3207039T/lt unknown
- 2015-10-14 DK DK15785014.0T patent/DK3207039T3/en active
- 2015-10-14 NZ NZ729688A patent/NZ729688A/en not_active IP Right Cessation
- 2015-10-14 ME MEP-2019-121A patent/ME03381B/me unknown
- 2015-10-14 TR TR2019/07755T patent/TR201907755T4/tr unknown
- 2015-10-14 PL PL15785014T patent/PL3207039T3/pl unknown
- 2015-10-14 SI SI201530696T patent/SI3207039T1/sl unknown
- 2015-10-14 PT PT15785014T patent/PT3207039T/pt unknown
- 2015-10-14 US US14/882,486 patent/US9745289B2/en active Active
- 2015-10-14 JP JP2017520427A patent/JP6279812B2/ja active Active
- 2015-10-14 AR ARP150103319A patent/AR102266A1/es unknown
- 2015-10-14 HU HUE15785014A patent/HUE043783T2/hu unknown
-
2017
- 2017-03-15 IL IL251200A patent/IL251200B/en active IP Right Grant
- 2017-03-31 PH PH12017500595A patent/PH12017500595B1/en unknown
- 2017-04-05 CL CL2017000827A patent/CL2017000827A1/es unknown
- 2017-04-05 CO CONC2017/0003305A patent/CO2017003305A2/es unknown
-
2019
- 2019-05-24 CY CY20191100554T patent/CY1121650T1/el unknown